Eventide Asset Management, LLC 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 12:13 pm Sale |
2024-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Eventide Asset Management, LLC | 4,475,054 6.280% |
-2,615,054 (-36.88%) |
Filing |
| 2024-11-06 2:47 pm Sale |
2024-10-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Eventide Asset Management, LLC | 7,090,108 9.970% |
-4,469,867 (-38.67%) |
Filing |
| 2023-12-11 5:15 pm Purchase |
2023-11-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Eventide Asset Management, LLC | 11,559,975 16.340% |
3,745,936 (+47.94%) |
Filing |
| 2023-10-10 3:40 pm Purchase |
2023-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Eventide Asset Management, LLC | 7,814,039 11.070% |
7,814,039 (New Position) |
Filing |